• Orexo disclosed initial preclinical in vivo pharmacokinetic results for an oral semaglutide tablet using its AmorphOX technology.
• Results have already been presented, showing the lead formulation matched the reference tablet’s bioavailability before any optimization.
• Work now shifts to formulation optimization with an industry partner, targeting bioavailability that could outperform marketed oral alternatives.
• The program broadens AmorphOX beyond intranasal use, supporting a strategy to enable needle-free delivery for peptides.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein.